JP2025508004A - 片頭痛の予防的治療 - Google Patents

片頭痛の予防的治療 Download PDF

Info

Publication number
JP2025508004A
JP2025508004A JP2024552730A JP2024552730A JP2025508004A JP 2025508004 A JP2025508004 A JP 2025508004A JP 2024552730 A JP2024552730 A JP 2024552730A JP 2024552730 A JP2024552730 A JP 2024552730A JP 2025508004 A JP2025508004 A JP 2025508004A
Authority
JP
Japan
Prior art keywords
atogepant
treatment
migraine
baseline
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552730A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508004A5 (https=
Inventor
トルーグマン，ジョエル
フィネガン，ミシェル
Original Assignee
アラガン ファーマスーティカルズ インターナショナル リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アラガン ファーマスーティカルズ インターナショナル リミテッド filed Critical アラガン ファーマスーティカルズ インターナショナル リミテッド
Publication of JP2025508004A publication Critical patent/JP2025508004A/ja
Publication of JP2025508004A5 publication Critical patent/JP2025508004A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024552730A 2022-03-09 2023-03-09 片頭痛の予防的治療 Pending JP2025508004A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202263269105P 2022-03-09 2022-03-09
US63/269,105 2022-03-09
US202263347265P 2022-05-31 2022-05-31
US63/347,265 2022-05-31
US202263404352P 2022-09-07 2022-09-07
US63/404,352 2022-09-07
US202363480365P 2023-01-18 2023-01-18
US63/480,365 2023-01-18
PCT/US2023/064027 WO2023173005A2 (en) 2022-03-09 2023-03-09 Preventive treatment of migraine

Publications (2)

Publication Number Publication Date
JP2025508004A true JP2025508004A (ja) 2025-03-21
JP2025508004A5 JP2025508004A5 (https=) 2026-03-09

Family

ID=87936018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552730A Pending JP2025508004A (ja) 2022-03-09 2023-03-09 片頭痛の予防的治療

Country Status (8)

Country Link
US (1) US20230321055A1 (https=)
EP (1) EP4489856A4 (https=)
JP (1) JP2025508004A (https=)
CN (1) CN119421710A (https=)
AU (1) AU2023231645A1 (https=)
CA (1) CA3244873A1 (https=)
MX (1) MX2024010878A (https=)
WO (1) WO2023173005A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN116390712A (zh) 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛
CA3206184A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
EP4408418A1 (en) 2021-09-27 2024-08-07 Allergan Pharmaceuticals International Limited Combination comprising atogepant for treating migraine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190374520A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US20210121541A1 (en) * 2019-07-05 2021-04-29 Allergan Pharmaceuticals International Limited CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders
CN116390712A (zh) * 2020-07-29 2023-07-04 阿勒根制药国际有限公司 治疗偏头痛

Also Published As

Publication number Publication date
US20230321055A1 (en) 2023-10-12
CN119421710A (zh) 2025-02-11
CA3244873A1 (en) 2023-09-14
WO2023173005A2 (en) 2023-09-14
MX2024010878A (es) 2024-09-17
WO2023173005A3 (en) 2023-11-23
EP4489856A4 (en) 2026-04-15
AU2023231645A1 (en) 2024-09-12
EP4489856A2 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
JP2025508004A (ja) 片頭痛の予防的治療
JP7183355B2 (ja) 片頭痛の処置における使用のためのラスミジタンとｃｇｒｐアンタゴニストとの併用療法
Larkin et al. A randomized, double-blind, comparative study of the efficacy of ketorolac tromethamine versus meperidine in the treatment of severe migraine
JP2025146837A (ja) 甲状腺眼症の治療方法
US12090148B2 (en) Treatment of migraine
GAY et al. Topical guanethidine therapy for endocrine lid retraction
Zou et al. Toxic epidermal necrolysis and Stevens‐Johnson syndrome after COVID‐19 infection and vaccination
Burns History of outcome measures for myasthenia gravis
Tomaszewski Postmenopausal overactive bladder
Nsaka et al. Real‐world evidence following a mandatory treatment break after a 1‐year prophylactic treatment with calcitonin gene‐related peptide (pathway) monoclonal antibodies
Berger et al. Lasmiditan for the treatment of migraines with or without aura in adults
WO2024081718A1 (en) Cgrp receptor antagonist for the treatment of migraine
KR20080055967A (ko) 섬유 근육통 증후군의 장기 치료를 위한 밀라시프란
Bielefeldt et al. Visceral pain
Al‐Qassab et al. Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study
US20250019437A1 (en) Anti-trem2 antibody and uses thereof
Schoenen et al. Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study
Gooderham et al. Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis
Schadt et al. Pharmacological treatment of disabling tremor
Bermudez et al. Bilateral acute Iris Transillumination syndrome following Oral moxifloxacin overdose
RU2828983C1 (ru) Способ лечения хронической мигрени
Viswanathan et al. Crystalline keratopathy due to intravenous immunoglobulin in a 12-year-old girl with Kawasaki disease
Clark Top 60 most important medications used in an orofacial pain treatment center
Franco et al. Disseminated Mycobacterium abscessus Mimicking Sarcoidosis: A Case of Successful Outcomes Against Clinical Expectations
Elgendy et al. Efficacy and Safety of Botulinum Toxin-A Injection into ischiocavernosus muscle in Treatment of Premature Ejaculation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260226